iX Biopharma (SGX:42C) received an in-principle approval from the Singapore Exchange Securities Trading for the listing and quotation of up to 75.8 million shares to raise around SG$6 million, according to a Thursday filing with the Singapore Exchange.
Shares of the specialty pharmaceutical and nutraceutical company were up over 2% in Friday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.